Difference between revisions of "Team:Cardiff Wales/practisepage1"

Line 113: Line 113:
  
 
</nav>
 
</nav>
 +
<head>
 +
<style>
 +
div.background {
 +
  background: url(https://pbs.twimg.com/profile_images/764485586522607616/Iqnj6DnC_400x400.jpg);
 +
  border: 2px solid black;
 +
}
 +
 +
div.transbox {
 +
  margin: 0px;
 +
  background-color: #ffff33;
 +
  border: 1px solid black;
 +
  opacity: 0.9;
 +
  filter: alpha(opacity=50);
 +
}
 +
 +
div.transbox p {
 +
  margin: 19%;
 +
  font-weight: bold;
 +
  color: #80ff80;
 +
}
 +
</style>
 +
</head>
 +
<body>
 +
 +
<div class="background">
 +
  <div class="transbox">
 +
    <p><h1 style="color:rgb(51, 153, 255);"><center>Cardiff iGEM team 2017 Project Brief</center></h1></p>
 +
  </div>
 +
</div>
 +
 +
</body>
 +
 
     <body>
 
     <body>
−
<h1><center>Cardiff 2017 Project Brief</center></h1>
 
 
<center>
 
<center>
 
     <section>
 
     <section>
Line 120: Line 151:
 
</section>
 
</section>
 
</center>
 
</center>
 +
<article>
 
<div class="clear"></div>
 
<div class="clear"></div>
 
<div class="column half_size" >
 
<div class="column half_size" >
Line 126: Line 158:
 
<p> The objective of this project was to take the native version of thyroid stimulating hormone (<abbr title="thyroid stimulating hormone">TSH</abbr>, AKA. Thyrotropin) which activates a cascade in the thyroid gland to produce thyroid hormones thyroxine (T4) and tri-iodotyrosine (T3).</p>
 
<p> The objective of this project was to take the native version of thyroid stimulating hormone (<abbr title="thyroid stimulating hormone">TSH</abbr>, AKA. Thyrotropin) which activates a cascade in the thyroid gland to produce thyroid hormones thyroxine (T4) and tri-iodotyrosine (T3).</p>
 
<p> By changing the amino acid sequence of the native TSH protein, we can disable the gland-activating effects of TSH, whilst still allowing TSH to bind to the gland. The engineered version still binds to the thyroid gland but does not activate it. Thus, it competitively inhibits the native TSH, and is potentially a therapeutic treatment for hyperthyroidism.</p>
 
<p> By changing the amino acid sequence of the native TSH protein, we can disable the gland-activating effects of TSH, whilst still allowing TSH to bind to the gland. The engineered version still binds to the thyroid gland but does not activate it. Thus, it competitively inhibits the native TSH, and is potentially a therapeutic treatment for hyperthyroidism.</p>
−
<body background="https://pbs.twimg.com/profile_images/764485586522607616/Iqnj6DnC_400x400.jpg">
+
</article>
 +
<body background="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSUtIbKfCP6i2VeNWZv3MoMzvXxBOcAIEQOX_Dn-DKqnmO9dnl8srDIArc">
 
</body>
 
</body>

Revision as of 20:50, 29 June 2017

Project

Cardiff iGEM team 2017 Project Brief

Creating a thyroid stimulating hormone antagonist by removing essential N-linked glycosylation groups

The objective of this project was to take the native version of thyroid stimulating hormone (TSH, AKA. Thyrotropin) which activates a cascade in the thyroid gland to produce thyroid hormones thyroxine (T4) and tri-iodotyrosine (T3).

By changing the amino acid sequence of the native TSH protein, we can disable the gland-activating effects of TSH, whilst still allowing TSH to bind to the gland. The engineered version still binds to the thyroid gland but does not activate it. Thus, it competitively inhibits the native TSH, and is potentially a therapeutic treatment for hyperthyroidism.